RecruitingNCT06376097
Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.
Implementation of a Lung Cancer Screening Program in a Public Service, Using Low-dose Tomography and Metabolomics Evaluation
Sponsor
AstraZeneca
Enrollment
1,000 participants
Start Date
Apr 19, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
Observational study that aims to evaluate the implementation of a lung cancer screening program in a smoker population included in a public heath service.
Eligibility
Min Age: 45 YearsMax Age: 74 Years
Plain Language Summary
Simplified for easier understanding
This study is testing a lung cancer screening program using low-dose CT scans (a type of chest X-ray that uses less radiation) along with blood tests to look for early signs of lung cancer in people who are or were heavy smokers.
**You may be eligible if...**
- You are between 45 and 74 years old
- You are a current smoker with at least 30 pack-years of smoking history, or a former smoker who quit less than 15 years ago
- You have never participated in a lung cancer screening program before
**You may NOT be eligible if...**
- You have an advanced chronic disease (heart, lung, liver, kidney, or metabolic) that limits life expectancy or ability to have surgery
- You are being treated for tuberculosis or a similar granulomatous disease
- You have a history of cancer that could spread to the lungs
- You are pregnant
- You are unable to undergo a chest CT scan
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06376097
Related Trials
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT048999082 locations
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer
NCT056329131 location
CARE Tool Study Aim 3
NCT072968873 locations
CHAMP Lung Cancer Screening Program
NCT075727733 locations
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT0605169512 locations